Study shows direct relationship between Alzheimer s tau protein and Cholesterol

60.00% credibility
 
Related

Adorable Japanese Hamster Eating A Carrot Before Sleeping Is Taking Over The Internet

Atma
2502 points

Drone captures beautiful footage of whales swimming near tiny human

Atma
616 points



Most recent

Boletin de Noticias

PENSAMIENTO LIBRE
14 points

Boletin de Noticias

PENSAMIENTO LIBRE
16 points

La cola de las verduras y la edad terciaria

Enrique TF
10 points

Bebé de 16 días de nacido supera el covid-19, el de menor edad del mundo

Bernardo Andrade Tapia
524 points

Docentes de Educación Inclusiva de Nariño exigen el pago de sus honorarios

Pablo Emilio Obando Acosta
202 points

La educación digital es para los pobres y los estúpidos

Enrique TF
30 points

Huérfano: La necesidad y el dolor, de tener que tomar el relevo

Enrique TF
18 points

Estados alterados... ¡Bah!

Juan Cantalatabla
8 points

Colombiana gana concurso de canto en Dubái

PENSAMIENTO LIBRE
112 points

Migrantes venezolanos atrapados en Rumichaca, frontera colombo-ecuatoriana

Bernardo Andrade Tapia
606 points
SHARE
TWEET
We have known for some years that Alzheimer’s disease is characterised by two types of lesions, amyloid plaques and degenerated tau protein. Cholesterol plays an important role in the physiopathology of this disease. Two French research teams (Inserm/CEA/University of Lille/University of Paris-Sud ) have just shown, in a rodent model, that overexpressing an enzyme that can eliminate excess cholesterol from the brain may have a beneficial action on the tau component of the disease, and completely correct it. This is the first time that a direct relationship has been shown between the tau component of Alzheimer’s disease and cholesterol. This work is published in the 10 September 2015 issue of Human Molecular Genetics.

Study shows direct relationship between Alzheimer   s tau protein and Cholesterol

xcess brain cholesterol cannot freely cross the blood-brain barrier; to be eliminated it must be converted into 24-hydroxycholesterol (24-OHC) by the enzyme CYP46A1 (cholesterol-24-hydroxylase). At Inserm Unit 1169, Nathalie, Cartier, coordinator of this work, and Patrick Aubourg, director of the unit, proposed the hypothesis that increasing the efflux of cholesterol from the brain by overexpressing CYP46A1 might have a beneficial effect on the elements of Alzheimer pathology.

The first step in this work made it possible to show that injecting a viral vector, AAV-CYP46A1, effectively corrects a mouse model of amyloid pathology of the disease, the APP23 mouse. CYP46A1 thus appears to be a therapeutic target for Alzheimer’s disease.

Conversely, in vivo inhibition of CYP46A1 in the mice, using antisense RNA molecules delivered by an AAV vector administered to the hippocampus, induces an increase in the production of Aß peptides, abnormal tau protein, neuronal death and hippocampal atrophy, leading to memory problems. Together these elements reproduce a phenotype mimicking Alzheimer’s disease.

These results demonstrate the key role of cholesterol in the disease, and confirm the relevance of CYP46A1 as a potential therapeutic target (work published in Brain on 3 July 2015).

Taken together, this work now enables the research team coordinated by Nathalie Cartier, Inserm Research Director, to propose a gene therapy approach for Alzheimer’s disease: intracerebral administration of a vector, AAV-CYP46A1, in patients with early and severe forms (1% of patients, familial forms) for whom there is no available treatment.

“To achieve this objective, we are carrying out all the preclinical steps of development and validation of the tools (vector, neurosurgical protocol, elements of monitoring) for demonstrating the efficacy and tolerance of the strategy, in order to submit an application for authorisation of a clinical trial,” explains Nathalie Cartier.

Fuente: neurosciencenews.com
SHARE
TWEET
To comment you must log in with your account or sign up!
Featured content